Pump.fun accounted for 92% of memecoin launches and 84% of launchpad trading volume across all chains in the 30 days ending Nov. 9, 2026. Most protocol revenue came from tokens with market caps under $250,000 or still on bonding curves, with fees totaling 2.5% per buy-sell cycle. Despite millions of launches, only a tiny fraction reached significant market caps, highlighting the high risk and rarity of success in memecoin launches. This data adds insight into the trading activity and revenue model of Pump.fun's platform.
Pump.fun's dominance in memecoin launches provides context for Pluang's cryptocurrency market snapshot as of Nov 12, 2026 05:22 WIB: among 50 major cryptocurrencies, 27 rose and 22 fell today. VeChain (VET) showed a modest 2.51% gain with a typical hold time of 149 days and a strong 96% sell order activity, contrasting with Curve DAO Token (CRV), which had a 2.23% decline but 100% buy order activity and a shorter hold time of 63 days. COTI fell 2.39% with 88% sell orders and a 123-day hold time, illustrating varied investor behavior across assets.
Ashland Inc.'s board of directors declared a quarterly cash dividend of $0.42 per share, payable on December 15, 2026, to shareholders of record as of December 1, 2026. This dividend reflects the company's ongoing commitment to returning value to sha...
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
